Treatment Options for Dupuytren’s Contracture

Save

The NEJM reports that in a randomized, controlled, head to head trial, collagenase injections were non-inferior to limited fasciectomy in the treatment of Dupuytren’s contracture.

Blue Collar Arthritis (10.25.2024)

Save

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Trends in DMARD Use in Juvenile Arthritis 2001-2022

Save

Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional DMARD use.

Potential OA Treatment - Chemokine CCL17 Inhibition

Save

Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.

Long-term Tofacitinib in Juvenile Idiopathic Arthritis

Save

SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA

Save

A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA).

Predictors of Adverse Pregnancy Outcomes in Lupus

Save

A large metanalysis of systemic lupus erythematosus (SLE) patients and pregnancy outcomes suggests that adverse pregnancy outcomes are more likely in those with lupus nephritis, chronic hypertension, SLE disease activity before and at concept

Anxiety and Depression Rising in Rheumatoid Arthritis

Save

Pain Relief in RA: JAK Better than TNF Inhibitors?

Save

Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.

ANA+ consult (10.18.2024)

Save

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Alendronate Atypical Fractures Back In Court

Save

Reuters reports that a U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck failed to warn that patients taking alendronate for osteoporosis may be at increased the risk of atypical femoral fractures.

Economic and Mental Health Burden of Rheumatoid Arthritis

Save

A University of Mississippi-led comprehensive study of a disorder that affects 4.27 million Americans nationwide is revealing just how significant its burdens are on patients' financial well-being and quality of life. Patients with rheumatoid arthritis pay an average of $3,383 more per year on health care expenditures than those without the disorder, according to the study published in ACR Open Rheumatology, the American College of Rheumatology’s journal.